Fraser A, Paul M, Attamna A, Leibovici L
Department of Medicine E, Beilinson Campus, Rabin Medical Center, Petah-Tiqva 49100, Israel.
Int J Tuberc Lung Dis. 2006 Jan;10(1):19-23.
The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), caused by Mycobacterium tuberculosis resistant to at least isoniazid (INH) and rifampicin, is a threat to global TB control.
To appraise evidence of the effectiveness of treatment of latent TB infection (LTBI) in people at risk for developing active MDR-TB.
Systematic review of comparative studies of people treated and not treated for LTBI following exposure to MDR-TB.
PubMed, EMBASE, LILACS and the Cochrane Library (December 2004).
Two observational studies met inclusion criteria. A prospective cohort study found individualised tailored treatment to be effective for preventing active TB in children (OR = 0.20, 95%CI 0.04-0.94), while a retrospective cohort study found INH not to be effective (OR = 0.46, 95%CI 0.07-2.32).
Evidence of the effects of treatment of LTBI in people exposed to MDR-TB is extremely limited in both quantity and quality. The increasing global spread of MDR-TB and the difficulties in treating it emphasise the need for effective preventive measures. Ideally, this issue should be addressed in a randomised controlled trial. Until such a trial is conducted, routine clinical data collected as part of existing TB control programmes could be useful and can be generated relatively easily.
由至少对异烟肼(INH)和利福平耐药的结核分枝杆菌引起的耐多药结核病(MDR-TB)的出现和传播对全球结核病控制构成威胁。
评估对有发生活动性耐多药结核病风险的人群进行潜伏性结核感染(LTBI)治疗效果的证据。
对接触耐多药结核病后接受和未接受LTBI治疗的人群进行比较研究的系统评价。
PubMed、EMBASE、LILACS和Cochrane图书馆(2004年12月)。
两项观察性研究符合纳入标准。一项前瞻性队列研究发现个体化定制治疗对预防儿童活动性结核病有效(OR = 0.20,95%CI 0.04 - 0.94),而一项回顾性队列研究发现异烟肼无效(OR = 0.46,95%CI 0.07 - 2.32)。
接触耐多药结核病的人群中LTBI治疗效果的证据在数量和质量上都极其有限。耐多药结核病在全球的不断传播及其治疗困难凸显了有效预防措施的必要性。理想情况下,这个问题应该在随机对照试验中解决。在进行此类试验之前,作为现有结核病控制项目一部分收集的常规临床数据可能会有用,并且相对容易获得。